1. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-18.
2. Lonardo A. Liver fibrosis: more than meets the eye. Ann Hepatol 2024;29:101479.
3. Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells 2020;9:875.
4. Ballestri S, Mantovani A, Girolamo MD, Baldelli E, Capitelli M, Lonardo A. Liver fibrosis in nonalcoholic fatty liver disease patients: noninvasive evaluation and correlation with cardiovascular disease and mortality. Metab Target Organ Damage 2023;3:1.
5. Geerts A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis 2001;21:311-35.
6. Sufleţel RT, Melincovici CS, Gheban BA, Toader Z, Mihu CM. Hepatic stellate cells - from past till present: morphology, human markers, human cell lines, behavior in normal and liver pathology. Rom J Morphol Embryol 2020;61:615-42.
7. ITO T, NEMOTO M. [Kupfer’s cells and fat storing cells in the capillary wall of human liver]. Okajimas Folia Anat Jpn 1952;24:243-58.
8. Tanuma Y, Ito T, Shibasaki S. Further electron-microscope studies on the human hepatic sinusoidal wall with special reference to the fat-storing cell. Arch Histol Jpn 1982;45:263-74.
9. Tanuma Y, Ohata M, Ito T. Electron microscopic studies on the sinusoidal cells in the monkey liver. Arch Histol Jpn 1983;46:401-26.
10. Ito T, Itoshima T, Ukida M, et al. Scanning electron microscopy of Ito’s fat-storing cells in the rat liver. Acta Med Okayama 1984;38:1-9.
11. Friedman SL, Roll FJ, Boyles J, Bissell DM. Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci U S A 1985;82:8681-5.
12. Ramadori G, Saile B. Portal tract fibrogenesis in the liver. Lab Invest 2004;84:153-9.
13. Forbes SJ, Russo FP, Rey V, et al. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology 2004;126:955-63.
14. Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 2003;37:493-503.
15. Montfort I, Pérez-Tamayo R. Collagenase in experimental carbon tetrachloride cirrhosis of the liver. Am J Pathol 1978;92:411-20.
16. Pérez-Tamayo R. Cirrhosis of the liver: a reversible disease? Pathol Annu 1979;14:183-213.
17. Hammel P, Couvelard A, O'Toole D, et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med 2001;344:418-23.
18. Bataller R, Brenner DA. Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin Liver Dis 2001;21:437-51.
19. Trivella JP, Martin P, Carrion AF. Novel targeted therapies for the management of liver fibrosis. Expert Opin Emerg Drugs 2020;25:59-70.
20. Lan Y, Wang H, Weng H, et al. The burden of liver cirrhosis and underlying etiologies: results from the Global Burden of Disease study 2019. Hepatol Commun 2023;7:e0026.
21. Wu XN, Xue F, Zhang N, et al. Global burden of liver cirrhosis and other chronic liver diseases caused by specific etiologies from 1990 to 2019. BMC Public Health 2024;24:363.
22. Rinella ME, Sookoian S. From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease. J Lipid Res 2024;65:100485.
23. Ciardullo S, Perseghin G. From NAFLD to MAFLD and MASLD: a tale of alcohol, stigma and metabolic dysfunction. Metab Target Organ Damage 2024;4:30.
24. Tan D, Chan KE, Wong ZY, et al. Global Epidemiology of cirrhosis: changing etiological basis and comparable burden of nonalcoholic steatohepatitis between males and females. Dig Dis 2023;41:900-12.
25. Hagström H, Lindfors A, Holmer M, et al. Etiologies and outcomes of cirrhosis in a large contemporary cohort. Scand J Gastroenterol 2021;56:727-32.
26. Lonardo A, Singal AK, Osna N, Kharbanda KK. Effect of cofactors on NAFLD/NASH and MAFLD. A paradigm illustrating the pathomechanics of organ dysfunction. Metab Target Organ Damage 2022;2:12.
27. Weiskirchen R, Weiskirchen S, Tacke F. Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts. F1000Res 2018;7:921.
28. Weiskirchen R, Weiskirchen S, Tacke F. Organ and tissue fibrosis: molecular signals, cellular mechanisms and translational implications. Mol Aspects Med 2019;65:2-15.
29. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008;134:1655-69.
30. Testerink N, Ajat M, Houweling M, et al. Replacement of retinyl esters by polyunsaturated triacylglycerol species in lipid droplets of hepatic stellate cells during activation. PLoS One 2012;7:e34945.
31. Delgado ME, Cárdenas BI, Farran N, Fernandez M. Metabolic reprogramming of liver fibrosis. Cells 2021;10:3604.
32. Shah V, Haddad FG, Garcia-Cardena G, et al. Liver sinusoidal endothelial cells are responsible for nitric oxide modulation of resistance in the hepatic sinusoids. J Clin Invest 1997;100:2923-30.
33. Chávez-Galán L, Olleros ML, Vesin D, Garcia I. Much more than M1 and M2 macrophages, there are also CD169+ and TCR+ macrophages. Front Immunol 2015;6:263.
34. Duque G, Descoteaux A. Macrophage cytokines: involvement in immunity and infectious diseases. Front Immunol 2014;5:491.
35. Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 2011;25:195-206.
36. Mitten EK, Baffy G. Mechanotransduction in the pathogenesis of non-alcoholic fatty liver disease. J Hepatol 2022;77:1642-56.
37. Baffy G, Portincasa P. Gut microbiota and sinusoidal vasoregulation in MASLD: a portal perspective. Metabolites 2024;14:324.
38. Aird WC. Phenotypic heterogeneity of the endothelium: II. Representative vascular beds. Circ Res 2007;100:174-90.
39. Augustin HG, Koh GY. A systems view of the vascular endothelium in health and disease. Cell 2024;187:4833-58.
40. Zhang YL, Li ZJ, Gou HZ, Song XJ, Zhang L. The gut microbiota-bile acid axis: a potential therapeutic target for liver fibrosis. Front Cell Infect Microbiol 2022;12:945368.
41. Arab JP, Arrese M, Shah VH. Gut microbiota in non-alcoholic fatty liver disease and alcohol-related liver disease: current concepts and perspectives. Hepatol Res 2020;50:407-18.
42. Costa CFFA, Sampaio-Maia B, Araujo R, et al. Gut microbiome and organ fibrosis. Nutrients 2022;14:352.
43. Winston JA, Theriot CM. Diversification of host bile acids by members of the gut microbiota. Gut Microbes 2020;11:158-71.
44. Larabi AB, Masson HLP, Bäumler AJ. Bile acids as modulators of gut microbiota composition and function. Gut Microbes 2023;15:2172671.
45. Barabási AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet 2011;12:56-68.
46. Ouyang X, Ghani A, Mehal WZ. Inflammasome biology in fibrogenesis. Biochim Biophys Acta 2013;1832:979-88.
47. Borkham-Kamphorst E, Weiskirchen R. The PDGF system and its antagonists in liver fibrosis. Cytokine Growth Factor Rev 2016;28:53-61.
48. Schon HT, Weiskirchen R. Immunomodulatory effects of transforming growth factor-β in the liver. Hepatobiliary Surg Nutr 2014;3:386-406.
49. Kang H, Seo E, Oh YS, Jun HS. TGF-β activates NLRP3 inflammasome by an autocrine production of TGF-β in LX-2 human hepatic stellate cells. Mol Cell Biochem 2022;477:1329-38.
50. Blas-García A, Apostolova N. Novel therapeutic approaches to liver fibrosis based on targeting oxidative stress. Antioxidants 2023;12:1567.
51. Ballestri S, Capitelli M, Fontana MC, et al. Direct oral anticoagulants in patients with liver disease in the era of non-alcoholic fatty liver disease global epidemic: a narrative review. Adv Ther 2020;37:1910-32.
52. Lonardo A, Zheng MH. Does an aspirin a day take the MASLD away? Adv Ther 2024;41:2559-75.
53. Oh H, Park HE, Song MS, Kim H, Baek JH. The therapeutic potential of anticoagulation in organ fibrosis. Front Med 2022;9:866746.
54. Weiskirchen R, Tacke F. The role of radiologic modalities in diagnosing nonalcoholic steatohepatitis (NASH) and fibrosis. Curr Hepatology Rep 2018;17:324-35.
55. Nascimbeni F, Ballestri S, Machado MV, et al. Clinical relevance of liver histopathology and different histological classifications of NASH in adults. Expert Rev Gastroenterol Hepatol 2018;12:351-67.
56. Ratziu V, Charlotte F, Heurtier A, et al; LIDO Study Group. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128:1898-906.
57. Ballestri S, Mantovani A, Baldelli E, et al. Liver fibrosis biomarkers accurately exclude advanced fibrosis and are associated with higher cardiovascular risk scores in patients with NAFLD or viral chronic liver disease. Diagnostics 2021;11:98.
58. Sanyal AJ, Castera L, Wong VW. Noninvasive assessment of liver fibrosis in NAFLD. Clin Gastroenterol Hepatol 2023;21:2026-39.
59. Boursier J, Canivet CM, Costentin C, et al. Impact of type 2 diabetes on the accuracy of noninvasive tests of liver fibrosis with resulting clinical implications. Clin Gastroenterol Hepatol 2023;21:1243-51.e12.
60. Sun W, Cui H, Li N, et al. Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: a meta-analysis study. Hepatol Res 2016;46:862-70.
61. Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology 2017;66:1486-501.
62. Ferraioli G, Wong VW, Castera L, et al. Liver ultrasound elastography: an update to the world federation for ultrasound in medicine and biology guidelines and recommendations. Ultrasound Med Biol 2018;44:2419-40.
63. Ballestri S, Nascimbeni F, Lugari S, Lonardo A, Francica G. A critical appraisal of the use of ultrasound in hepatic steatosis. Expert Rev Gastroenterol Hepatol 2019;13:667-81.
64. de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C; Baveno VII Faculty. Baveno VII - renewing consensus in portal hypertension. J Hepatol 2022;76:959-74.
65. Wattacheril JJ, Abdelmalek MF, Lim JK, Sanyal AJ. AGA clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review. Gastroenterology 2023;165:1080-8.
66. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; Clinical Practice Guideline Panel; Chair:; EASL Governing Board representative:; Panel members:. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol 2021;75:659-89.
67. Newsome PN, Sasso M, Deeks JJ, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol 2020;5:362-73.
68. Mózes FE, Lee JA, Selvaraj EA, et al; LITMUS Investigators. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut 2022;71:1006-19.
69. Patel K, Sebastiani G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep 2020;2:100067.
70. McPherson S, Hardy T, Dufour JF, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol 2017;112:740-51.
71. Petta S, Wai-Sun Wong V, Bugianesi E, et al. Impact of obesity and alanine aminotransferase levels on the diagnostic accuracy for advanced liver fibrosis of noninvasive tools in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2019;114:916-28.
72. Zhang X, Wong GL, Wong VW. Application of transient elastography in nonalcoholic fatty liver disease. Clin Mol Hepatol 2020;26:128-41.
73. Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, et al. Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study. Gastroenterology 2018;155:443-57.e17.
74. Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut 2024;73:691-702.
75. Taylor RS, Taylor RJ, Bayliss S, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology 2020;158:1611-25.e12.
76. Cianci N, Subhani M, Hill T, et al. Prognostic non-invasive biomarkers for all-cause mortality in non-alcoholic fatty liver disease: a systematic review and meta-analysis. World J Hepatol 2022;14:1025-37.
77. Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 2017;65:1557-65.
78. Ciardullo S, Cannistraci R, Muraca E, Zerbini F, Perseghin G. Liver fibrosis, NT-ProBNP and mortality in patients with MASLD: a population-based cohort study. Nutr Metab Cardiovasc Dis 2024;34:963-71.
79. Collier A, Curran C, Cameron L, Wild SH, Byrne CD. Liver fibrosis markers and all cause mortality in people with type 2 diabetes: a population based study (The Ayrshire Diabetes Outcomes Cohort (ADOC) study). Diabetes Obes Metab 2023;25:2659-68.
80. Choi SW, Kweon SS, Lee YH, Ryu SY, Nam HS, Shin MH. Association of liver fibrosis biomarkers with overall and CVD mortality in the Korean population: the Dong-gu study. PLoS One 2022;17:e0277729.
81. Vieira Barbosa J, Milligan S, Frick A, et al. Fibrosis-4 index as an independent predictor of mortality and liver-related outcomes in NAFLD. Hepatol Commun 2022;6:765-79.
82. Baik M, Nam HS, Heo JH, et al. Advanced liver fibrosis predicts unfavorable long-term prognosis in first-ever ischemic stroke or transient ischemic attack. Cerebrovasc Dis 2020;49:474-80.
83. Cao YX, Zhang M, Zhang HW, et al. Impact of liver fibrosis score on prognosis in patients with previous myocardial infarction: a prospective cohort study. Liver Int 2021;41:1294-304.
84. Jin JL, Zhang HW, Cao YX, et al. Liver fibrosis scores and coronary atherosclerosis: novel findings in patients with stable coronary artery disease. Hepatol Int 2021;15:413-23.
85. Oh TJ, Kim K, Moon JH, Choi SH, Cho NH, Jang HC. Liver fibrosis indices for the prediction of mortality in korean subjects: a 16-year prospective cohort study. J Endocr Soc 2021;5:bvab123.
86. Chung GE, Han K, Lee KN, et al. Combined effects of chronic kidney disease and nonalcoholic fatty liver disease on the risk of cardiovascular disease in patients with diabetes. Biomedicines 2022;10:1245.
87. Yan Z, Liu Y, Li W, et al. Liver fibrosis scores and prognosis in patients with cardiovascular diseases: a systematic review and meta-analysis. Eur J Clin Invest 2022;52:e13855.
88. Mascherbauer K, Donà C, Koschutnik M, et al. Hepatic T1-time predicts cardiovascular risk in all-comers referred for cardiovascular magnetic resonance: a post-hoc analysis. Circ Cardiovasc Imaging 2022;15:e014716.
89. Lee J, Jo G, Park D, Jun HJ, Bae JH, Shin MJ. The association between advanced liver fibrosis and mortality is modified by dietary quality among Korean adults: results from the Korea National Health and Nutrition Examination Survey with mortality data. Nutrients 2023;15:1501.
90. Seo YG, Polyzos SA, Park KH, Mantzoros CS. Fibrosis-4 index predicts long-term all-cause, cardiovascular and liver-related mortality in the adult Korean population. Clin Gastroenterol Hepatol 2023;21:3322-35.
91. Guan L, Li L, Zou Y, Zhong J, Qiu L. Association between FIB-4, all-cause mortality, cardiovascular mortality, and cardiovascular disease risk among diabetic individuals: NHANES 1999-2008. Front Cardiovasc Med 2023;10:1172178.
92. Nakashima M, Nakamura K, Nishihara T, et al. Association between cardiovascular disease and liver disease, from a clinically pragmatic perspective as a cardiologist. Nutrients 2023;15:748.
93. Roca-Fernandez A, Banerjee R, Thomaides-Brears H, et al. Liver disease is a significant risk factor for cardiovascular outcomes - a UK Biobank study. J Hepatol 2023;79:1085-95.
94. Lu C, Chen Y, Zhang Y, Zhao X. Liver fibrosis scores and coronary artery disease: novel findings in patients with metabolic dysfunction-associated fatty liver disease. Diabetes Metab Syndr Obes 2023;16:2627-37.
95. Mitten EK, Portincasa P, Baffy G. Portal hypertension in nonalcoholic fatty liver disease: challenges and paradigms. J Clin Transl Hepatol 2023;11:1201-11.
96. Wan Y, Li X, Slevin E, et al. Endothelial dysfunction in pathological processes of chronic liver disease during aging. FASEB J 2022;36:e22125.
97. Cetin EG, Demir N, Sen I. The relationship between insulin resistance and liver damage in non-alcoholic fatty liver patients. Sisli Etfal Hastan Tip Bul 2020;54:411-5.
98. Kim GA, Lee HC, Choe J, et al. Association between non-alcoholic fatty liver disease and cancer incidence rate. J Hepatol 2017;68:140-6.
99. Peleg N, Sneh Arbib O, Issachar A, Cohen-Naftaly M, Braun M, Shlomai A. Noninvasive scoring systems predict hepatic and extra-hepatic cancers in patients with nonalcoholic fatty liver disease. PLoS One 2018;13:e0202393.
100. Liu SS, Ma XF, Zhao J, et al. Association between nonalcoholic fatty liver disease and extrahepatic cancers: a systematic review and meta-analysis. Lipids Health Dis 2020;19:118.
101. Lee JM, Park YM, Yun JS, et al. The association between nonalcoholic fatty liver disease and esophageal, stomach, or colorectal cancer: national population-based cohort study. PLoS One 2020;15:e0226351.
102. Veracruz N, Hameed B, Saab S, Wong RJ. The association between nonalcoholic fatty liver disease and risk of cardiovascular disease, stroke, and extrahepatic cancers. J Clin Exp Hepatol 2021;11:45-81.
103. Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. Gut 2022;71:778-88.
104. Thomas JA, Kendall BJ, Dalais C, Macdonald GA, Thrift AP. Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Cancer 2022;173:250-62.
105. Muhamad NA, Maamor NH, Leman FN, et al. The global prevalence of nonalcoholic fatty liver disease and its association with cancers: systematic review and meta-analysis. Interact J Med Res 2023;12:e40653.
106. Xie J, Gao H, Liu C, Pan Y, Xu C, Xu L. Causal association of nonalcoholic fatty liver disease with 22 extrahepatic cancers: a Mendelian randomization study. Hepatol Res 2024;54:261-71.
107. Thomas JA, Kendall BJ, El-Serag HB, Thrift AP, Macdonald GA. Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol 2024;9:159-69.
108. Loria P, Marchesini G, Nascimbeni F, et al. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. Atherosclerosis 2014;232:99-109.
109. Ballestri S, Zona S, Targher G, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol 2016;31:936-44.
110. Mantovani A, Csermely A, Petracca G, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2021;6:903-13.
111. Henson JB, Simon TG, Kaplan A, Osganian S, Masia R, Corey KE. Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2020;51:728-36.
112. Simon TG, Roelstraete B, Hagström H, Sundström J, Ludvigsson JF. Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. Gut 2022;71:1867-75.
113. Hagström H, Nasr P, Ekstedt M, et al. Cardiovascular risk factors in non-alcoholic fatty liver disease. Liver Int 2019;39:197-204.
114. Park JH, Koo BK, Kim W, Kim WH; Innovative Target Exploration of NAFLD (ITEN) Consortium. Histological severity of nonalcoholic fatty liver disease is associated with 10-year risk for atherosclerotic cardiovascular disease. Hepatol Int 2021;15:1148-59.
115. Han E, Lee YH, Lee JS, et al. Fibrotic burden determines cardiovascular risk among subjects with metabolic dysfunction-associated fatty liver disease. Gut Liver 2022;16:786-97.
116. Arai T, Atsukawa M, Tsubota A, et al. Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver disease. Sci Rep 2021;11:15938.
117. Yi M, Peng W, Teng F, Kong Q, Chen Z. The role of noninvasive scoring systems for predicting cardiovascular disease risk in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2022;34:1277-84.
118. Chen S, Xue H, Huang R, Chen K, Zhang H, Chen X. Associations of MAFLD and MAFLD subtypes with the risk of the incident myocardial infarction and stroke. Diabetes Metab 2023;49:101468.
119. Park J, Kim G, Kim BS, et al. The association between changes in hepatic steatosis and hepatic fibrosis with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study. Diabetes Res Clin Pract 2022;194:110191.
120. Corbin KD, Dagogo-Jack S, Cannon CP, et al. Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: analyses from VERTIS CV, a randomized trial of the sodium-glucose cotransporter-2 inhibitor ertugliflozin. Diabetes Obes Metab 2023;25:758-66.
121. Li J, Xiang Y, Han J, et al. Retinopathy as a predictive indicator for significant hepatic fibrosis according to T2DM status: a cross-sectional study based on the national health and nutrition examination survey data. Ann Hepatol 2024;29:101478.
122. Trivedi HD, Tran Q, Fricker Z, Curry MP, Li JX, Lai M. Type 2 diabetes complications are associated with liver fibrosis independent of hemoglobin A1c. Ann Hepatol 2023;28:101087.
123. Mantovani A, Dauriz M, Sandri D, et al. Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: an updated meta-analysis. Liver Int 2019;39:758-69.
124. Park HE, Lee H, Choi SY, Kim HS, Chung GE. The risk of atrial fibrillation in patients with non-alcoholic fatty liver disease and a high hepatic fibrosis index. Sci Rep 2020;10:5023.
125. Wang Z, Wang Y, Luo F, et al. Impact of advanced liver fibrosis on atrial fibrillation recurrence after ablation in non-alcoholic fatty liver disease patients. Front Cardiovasc Med 2022;9:960259.
126. Liu X, Chen W, Shao W, et al. Liver fibrosis scores and atrial fibrillation incidence in heart failure with preserved ejection fraction. ESC Heart Fail 2022;9:3985-94.
127. Mantovani A, Byrne CD, Benfari G, Bonapace S, Simon TG, Targher G. Risk of heart failure in patients with nonalcoholic fatty liver disease: JACC review topic of the week. J Am Coll Cardiol 2022;79:180-91.
128. Salah HM, Pandey A, Van Spall HGC, Michos ED, McGarrah RW, Fudim M. Meta-analysis of nonalcoholic fatty liver disease and incident heart failure. Am J Cardiol 2022;171:180-1.
129. Iwasaki Y, Shiina K, Matsumoto C, et al. Correlation of the fatty liver index with the pathophysiological abnormalities associated with cardiovascular risk markers in japanese men without any history of cardiovascular disease: comparison with the fibrosis-4 score. J Atheroscler Thromb 2021;28:524-34.
130. Boeckmans J, Sandrin L, Knackstedt C, Schattenberg JM. Liver stiffness as a cornerstone in heart disease risk assessment. Liver Int 2024;44:344-56.
131. Long MT, Zhang X, Xu H, et al. Hepatic fibrosis associates with multiple cardiometabolic disease risk factors: the framingham heart study. Hepatology 2021;73:548-59.
132. Tang R, Abeysekera KWM, Howe LD, Hughes AD, Fraser A. Non-alcoholic fatty liver and fibrosis is associated with cardiovascular structure and function in young adults. Hepatol Commun 2023;7:e0087.
133. Kuznetsova A, Dolgushina A, Savochkina A, et al. Liver stiffness is associated with the burden of carotid and systemic atherosclerosis in an unorganized cohort of patients 40-64 years old. Diagnostics 2022;12:2336.
134. Song Y, Dang Y, Wang P, Tian G, Ruan L. CHD is associated with higher grades of NAFLD predicted by liver stiffness. J Clin Gastroenterol 2020;54:271-7.
135. Shili-Masmoudi S, Wong GL, Hiriart JB, et al. Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease. Liver Int 2020;40:581-9.
136. Ciardullo S, Cannistraci R, Mazzetti S, Mortara A, Perseghin G. Nonalcoholic fatty liver disease, liver fibrosis and cardiovascular disease in the adult US population. Front Endocrinol 2021;12:711484.
137. Petta S, Sebastiani G, Viganò M, et al. Monitoring occurrence of liver-related events and survival by transient elastography in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease. Clin Gastroenterol Hepatol 2021;19:806-15.e5.
138. Kleef LA, Lu Z, Ikram MA, de Groot NMS, Kavousi M, de Knegt RJ. Liver stiffness not fatty liver disease is associated with atrial fibrillation: the Rotterdam study. J Hepatol 2022;77:931-938.
139. Ostovaneh MR, Ambale-Venkatesh B, Fuji T, et al. Association of liver fibrosis with cardiovascular diseases in the general population: the Multi-Ethnic Study of Atherosclerosis (MESA). Circ Cardiovasc Imaging 2018;11:e007241.
140. Tamaki N, Higuchi M, Kurosaki M, Loomba R, Izumi N; MRCH Liver Study Group. Risk difference of liver-related and cardiovascular events by liver fibrosis status in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2022;20:1171-73.e2.
141. Lugari S, Baldelli E, Lonardo A. Metabolic primary liver cancer in adults: risk factors and pathogenic mechanisms. Metab Target Organ Damage 2023;3:5.
142. Hagström H, Kechagias S, Ekstedt M. Risk for hepatic and extra-hepatic outcomes in nonalcoholic fatty liver disease. J Intern Med 2022;292:177-89.
143. Mantovani A, Lonardo A, Stefan N, Targher G. Metabolic dysfunction-associated steatotic liver disease and extrahepatic gastrointestinal cancers. Metabolism 2024;160:156014.
144. Lonardo A. Extra-hepatic cancers in metabolic fatty liver syndromes. Explor Dig Dis 2023;2:11-7.
145. Lonardo A. Is liver fibrosis a risk factor for gynecological cancers? Metab Target Organ Damage 2024;4:7.
146. Kim MC, Park JG, Jang BI, Lee HJ, Lee WK. Liver fibrosis is associated with risk for colorectal adenoma in patients with nonalcoholic fatty liver disease. Medicine 2019;98:e14139.
147. Chakraborty D, Wang J. Nonalcoholic fatty liver disease and colorectal cancer: correlation and missing links. Life Sci 2020;262:118507.
148. Ait-ahmed Y, Lafdil F. Novel insights into the impact of liver inflammatory responses on primary liver cancer development. Liver Research 2023;7:26-34.
149. Yu J, Chen X, Yang X, Zhang B. Understanding gut dysbiosis for hepatocellular carcinoma diagnosis and treatment. Trends Endocrinol Metab 2024;35:1006-20.
150. Wong ND, Zhao Y, Patel R, et al. Cardiovascular risk factor targets and cardiovascular disease event risk in diabetes: a pooling project of the atherosclerosis risk in communities study, multi-ethnic study of atherosclerosis, and jackson heart study. Diabetes Care 2016;39:668-76.
151. Siniawski D, Masson G, Masson W, et al. Residual cardiovascular risk, use of standard care treatments, and achievement of treatment goals in patients with cardiovascular disease. Int J Cardiol Cardiovasc Risk Prev 2023;18:200198.
152. Jamalinia M, Lonardo A. Perspective article: Determinants and assessment of cardiovascular risk in steatotic liver disease owing to metabolic dysfunction-addressing the challenge. Metab Target Organ Damage 2024;4:23.
153. Moreno-Del Castillo MC, Sanchez-Rodriguez A, Hernandez-Buen Abad JJ, et al. Importance of evaluating cardiovascular risk and hepatic fibrosis in patients with newly diagnosed nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2019;17:997-9.
154. Lauridsen BK, Stender S, Kristensen TS, et al. Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279 013 individuals. Eur Heart J 2018;39:385-93.
155. Yeung SL, Borges MC, Wong THT, Lawlor DA, Schooling CM. Evaluating the role of non-alcoholic fatty liver disease in cardiovascular diseases and type 2 diabetes: a Mendelian randomization study in Europeans and East Asians. Int J Epidemiol 2023;52:921-31.
156. Ren Z, Simons PIHG, Wesselius A, Stehouwer CDA, Brouwers MCGJ. Relationship between NAFLD and coronary artery disease: a Mendelian randomization study. Hepatology 2023;77:230-8.
157. Wanless IR. The role of vascular injury and congestion in the pathogenesis of cirrhosis: the congestive escalator and the parenchymal extinction sequence. Curr Hepatology Rep 2020;19:40-53.
158. Poisson J, Lemoinne S, Boulanger C, et al. Liver sinusoidal endothelial cells: physiology and role in liver diseases. J Hepatol 2017;66:212-27.
159. Adolph TE, Grander C, Moschen AR, Tilg H. Liver-microbiome axis in health and disease. Trends Immunol 2018;39:712-23.
160. Hammoutene A, Rautou PE. Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease. J Hepatol 2019;70:1278-91.
161. Hsu CL, Schnabl B. The gut-liver axis and gut microbiota in health and liver disease. Nat Rev Microbiol 2023;21:719-33.
162. Pandey E, Nour AS, Harris EN. Prominent receptors of liver sinusoidal endothelial cells in liver homeostasis and disease. Front Physiol 2020;11:873.
163. Stefan N, Lonardo A, Targher G. Role of steatotic liver disease in prediction and prevention of cardiometabolic diseases. Nat Rev Gastroenterol Hepatol 2024;21:136-7.
164. Alkhouri N, Tamimi TA, Yerian L, Lopez R, Zein NN, Feldstein AE. The inflamed liver and atherosclerosis: a link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk. Dig Dis Sci 2010;55:2644-50.
165. Arulanandan A, Ang B, Bettencourt R, et al. Association between quantity of liver fat and cardiovascular risk in patients with nonalcoholic fatty liver disease independent of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2015;13:1513-20.e1.
166. Bril F, Sninsky JJ, Baca AM, et al. Hepatic steatosis and insulin resistance, but not steatohepatitis, promote atherogenic dyslipidemia in NAFLD. J Clin Endocrinol Metab 2016;101:644-52.
167. Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol 2018;68:335-52.
168. Jamalinia M, Zare F, Noorizadeh K, Bagheri Lankarani K. Systematic review with meta-analysis: steatosis severity and subclinical atherosclerosis in metabolic dysfunction-associated steatotic liver disease. Aliment Pharmacol Ther 2024;59:445-58.
169. las Heras N, Aller MA, Arias J, Lahera V. The risk association between experimental portal hypertension and an aortic atherosclerosis-like disease. Hepatology 2013;57:421-2.
170. Mitten EK, Baffy G. Mechanobiology in the development and progression of non-alcoholic fatty liver disease: an updated review. Metab Target Organ Damage 2023;3:2.
171. Gracia-Sancho J, Maeso-Díaz R, Fernández-Iglesias A, Navarro-Zornoza M, Bosch J. New cellular and molecular targets for the treatment of portal hypertension. Hepatol Int 2015;9:183-91.
172. Sharpton SR, Loomba R. Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC. Hepatology 2023;78:1896-906.
173. Lonardo A, Roncucci L. The “obese liver” and gastrointestinal cancer risk. Transl Gastroenterol Hepatol 2020;5:44.
174. Tadokoro T, Morishita A, Masaki T. Diagnosis and therapeutic management of liver fibrosis by microRNA. Int J Mol Sci 2021;22:8139.
Comments
Comments must be written in English. Spam, offensive content, impersonation, and private information will not be permitted. If any comment is reported and identified as inappropriate content by OAE staff, the comment will be removed without notice. If you have any queries or need any help, please contact us at support@oaepublish.com.